Abstract
Bifidobacterium longum is an attractive candidate for delivering biologically active proteins by the mucosal route due to its non-pathogenic and colonizing properties. Enterovirus 71 (EV71) has aroused widespread attention recently due to several epidemics, and great attention should be paid to the fact that there are currently no effective antiviral drugs or vaccines against EV71 infection. In this report, we described a recombinant B. longum that could be used to develop an oral vaccine against EV71 infection. A VP1 expression vector (pBBADs-VP1) was constructed by amplifying the EV71 VP1 gene and inserting it into the E. coli–Bifidobacterium shuttle expression vector pBBAD/Xs. Then, the expression of VP1 protein in pBBADs-VP1-transformed bacteria was demonstrated by western blot. In vivo studies indicated that oral immunization of BALB/c mice with pBBADs-VP1-transformed bacteria induced potent immune responses against EV71 infection, including virus-neutralising titers, anti-EV71-VP1 antibody and the induction of Th1 immune responses in the spleen and Peyer’s patches. Importantly, immunization of mother mice with this recombinant VP1-expressing B. longum conferred protection to neonatal mice. These results demonstrate that the novel oral vaccine utilizing B. longum expressing the VP1 protein might successfully elicit a specific immune response against EV71 infection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- EV71:
-
Enterovirus 71
- IFN-γ:
-
Interferon-γ
- TNF-α:
-
Tumor necrosis factor α
- GFP:
-
Green fluorescent protein
- MNCs:
-
Mononuclear cells
- IPTG:
-
Isopropyl β-D-thiogalactopyranoside
- BSA:
-
Bovine serum albumin
- PPs:
-
Peyer’s patches
- B. longum :
-
Bifidobacterium longum
- TCID:
-
Tissue culture infectious dose
- CPE:
-
Cytopathic effect
References
Shindarov LM, Chumakov MP, Voroshilova MK, Bojinov S, Vasilenko SM, Kirov ID, Kamenov E, Leshchinskaya EV, Mitov G, Robinson IA, Sivchev S, Staikov S (1979) Epidemiological, clinical and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol 23:284–295
McMinn PC (2002) An Overview of the evolution of enterovirus71 and its clinical and public health significance. FEMS Microbiol Rev 26:91–107
Liao HT, Hung KL (2001) Neurologic involvement in an outbreak of enterovirus 71 infection: A hospital-based study. Acta Paediatr Taiwan 42:27–32
Wu CN, Lin YC, Cathy Y, Liao NS, Shih SR, Ho MS (2002) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20:895–904
Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF, Chen CM (2008) Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 26:2882–2889
Chen HF, Chang MH, Chiang BL, Jeng ST (2006) Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24:2944–2951
Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z, Lu S (2010) EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 28:3516–3521
Zhang D, Lu J, Lu J (2010) Enterovirus 71 vaccine: close but still far. Int J Infect Dis 14:e739–e743
Lee MS, Chang LY (2010) Development of enterovirus 71 vaccines. Expert Rev Vaccines 9:149–156
Chen CW, Lee YP, Wang YF, Yu CK (2011) Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 29:2772–2776
Wong HT, Cheng SC, Sin FW, Chan EW, Sheng ZT, Xie Y (2002) A DNA vaccine against foot-and-mouth disease elicits an immune response in swine which is enhanced by co-administration with interleukin-2. Vaccine 20:2641–2647
Ho SY, Chua SQ, Foo DG, Locht C, Chow VT, Poh CL, Alonso S (2008) Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates. Infect Immun 76:111–119
Chiu CH, Chu C, He CC, Lin TY (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8:1671–1678
Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26:1855–1862
Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P (2011) Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29:4362–4372
Long RT, Zeng WS, Chen LY, Guo J, Lin YZ, Huang QS, Luo SQ (2010) Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice. Int J Obes (Lond) 34:712–719
Yasui H, Ohwaki M (1991) Enhancement of immune response in Peyer’s patch cells cultured with Bifidobacterium breve. J Dairy Sci 74:1187–1195
Takata T, Shirakawa T, Kawasaki Y, Kinoshita S, Gotoh A, Kano Y, Kawabata M (2006) Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the mucosal immunization in a mouse model. J Gene Med 8:1341–1346
Yamamoto S, Wada J, Katayama T, Jikimoto T, Nakamura M, Kinoshita S, Lee KM, Kawabata M, Shirakawa T (2010) Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model. Vaccine 28:6684–6691
Park JH, Um JI, Lee BJ, Goh JS, Park SY, Kim WS, Kim PH (2002) Encapsulated Bifidobacterium bifidum potentiates intestinal IgA production. Cell Immunol 219:22–27
Mullie C, Yazourh A, Thibault H, Odou MF, Singer E, Kalach N, Kremp O, Romond MB (2004) Increased poliovirus- specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: a randomized, double-blind, placebo-controlled trial. Pediatr Res 56:791–795
Yasui H, Nagaoka N, Hayawaka K (1994) Augmentation of anti-influenza virus hemagglutinin antibody production by Peyer’s patch cells with Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol 1:244–246
Yu Z, Zeng Z, Huang Z, Lian J, Yang J, Deng Q, Zeng W (2010) Increased mRNA expression of interferon- induced Mx1 and immunomodulation following oral administration of IFN-alpha2b-transformed B. longum to mice. Arch Microbiol 192:633–638
Acknowledgments
This work was supported by two grants from Shenzhen Scientific Research Program of the People’s Republic of China (no. 200801020 and no. 201001023) and Science and Technology Planning Project of Guangdong Province, China (no. 2010B011000005).
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Yu, Z., Huang, Z., Sao, C. et al. Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71. Arch Virol 158, 1071–1077 (2013). https://doi.org/10.1007/s00705-012-1589-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00705-012-1589-z